Huons and Boryung Sign Joint Sales Agreement for Hair Loss Drug 'Pinjuve Spray'

Huons recently announced on the 21st that it has signed a joint sales and distribution agreement with Boryung for the male pattern hair loss treatment 'Pinjuve Spray.'

Boryeong CEO Jang Doo-hyun (left) and Huons CEO Yoon Sang-bae are taking a commemorative photo after signing a joint promotion contract for the hair loss treatment Pinjuve Spray at the Boryeong headquarters.
[Photo by Huons]

Pinjuve Spray is a hair loss treatment developed by Almirall, a global pharmaceutical company specializing in dermatological drugs. It contains finasteride, which is prescribed for androgenetic alopecia in adult men, and has been developed in a spray form rather than oral medication, allowing direct application to the affected areas. Compared to oral drugs, it lowers the blood concentration of finasteride to reduce side effects, while maintaining treatment efficacy equivalent to 1mg oral finasteride.

Boryung secured the exclusive domestic distribution rights for Pinjuve Spray in January last year and obtained domestic product approval in September of the same year.

Through this agreement, Huons will be responsible for domestic distribution and sales at dermatology clinics and general urology clinics. Boryung plans to build a sales network targeting general hospitals, internal medicine clinics, family medicine clinics, and general clinics. Huons aims to maximize synergy with Boryung based on its high understanding and know-how of the non-reimbursed pharmaceutical market.

Yoon Sang-bae, CEO of Huons, said, "We are pleased to provide a clinically safe and effective hair loss treatment to domestic patients through this partnership with Boryung. We will strive to establish Pinjuve Spray as a new treatment option in the hair loss treatment field by leveraging Huons’ excellent sales capabilities focused on dermatology and urology and its strengths in the non-reimbursed pharmaceutical market."

Jang Doo-hyun, CEO of Boryung, stated, "By strengthening focus on the core areas held by both companies, we expect to expand market share rapidly. We will work closely to provide differentiated treatment options to medical professionals and patients."